Complications after hip revision arthroplasty
Conditions
Interventions
Postoperative tranexamic acid intravenous administration for 1 day group:The patient was given 1g tranexamic acid +250ml 0.9% saline (qd) intravenically at the same time point on the first day after s
Postoperative tranexamic acid intravenous administration for 5 days group:1g tranexamic acid +250ml 0.9% normal saline (qd) was given intravenically at the same time point on the first day after surge
Blank control group:Do not use tranexamic acid after surgery (including intravenous, topical or oral use, etc.)
Sponsors
First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Age =18 years old, gender is not limited; (2) Surgical complications after total hip arthroplasty diagnosed in our hospital and requiring surgical treatment, including but not limited to: Periprosthetic infection; Periprosthetic fracture; Prosthesis looseness; Repeated dislocation after total hip arthroplasty could not be improved by manual reduction and open reduction; The intractable pain after total hip arthroplasty. (3)Patients undergoing hip revision arthroplasty [including total hip joint revision, partial hip joint revision (acetabulum revision or femoral stem revision)], excluding patients who only received replacement of the head and insert; (4) Voluntary and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Allergic to tranexamic acid; (2) Previous history of thromboembolism (including deep venous thromboembolism, pulmonary embolism, cerebral infarction, transient ischemic attack, myocardial infarction or angina pectoris within 6 months); (3) Progressive renal insufficiency (stage 4 and above) or glomerular filtration rate less than 30ml/min; (4) Congenital or acquired coagulation dysfunction; (5) Long-term use of anticoagulants or antiplatelet drugs due to other diseases (except routine perioperative anticoagulation with a single subcutaneous injection of 40mg low molecular weight heparin sodium 12 hours before and 12 hours after surgery); (6) Preoperative assessment was American Society of Anesthesiologists (ASA) Level 4 (7) Preoperative prothrombin time (PT) International standardized ratio (INR) >1.4 (8) Need to receive radiotherapy and chemotherapy due to neoplastic diseases; (9) severe immunodeficiency diseases (such as stage 3 HIV, sickle cell anemia, splenectomy, etc.); (10) Have a history of drug abuse; (11) Treatment of bone marrow or other transplants with immunosuppressive drugs; (12) Pregnant, parturient and lactating women; (13) Patients with acquired visual impairment; (14) Patients with a history of convulsions; (15) Participating in other clinical trials; (16)The researchers considered other reasons not suitable for clinical trial participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative hemoglobin reduction; | — |
Secondary
| Measure | Time frame |
|---|---|
| Calculated blood loss;Postoperative blood transfusion rate and blood transfusion volume;Incidence of postoperative venous thrombosis of lower extremity; | — |
Countries
China
Contacts
Public ContactLi Cao
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed